A new approach to etiotropic therapy ARVI in children

Cover Page

Cite item

Full Text

Abstract

Aim. Confirmation of the efficacy and safety of the drug riamilovir (Triazavirin®), 100 mg capsules, in children aged 12–17 years with the diagnosis of acute viral respiratory infection (ARVI).

Materials and methods. The multicenter study included 269 patients diagnosed with acute viral respiratory infection (ICD-10 code: J00, J02, J02.9, J04, J04.0, J04.1, J04.2, J06, J06.0, J06.9) in the presence of clinical manifestations and confirmation of the etiology of the disease by laboratory tests (PCR method). Patients were included in the study after one of the patient's parents/adoptive parents and the patient signed an informed consent to participate in the study. The interval between the appearance of the first symptoms of the disease and the inclusion of the patient in the study did not exceed 36 hours.

Results. As a result of a clinical study, the efficacy and safety of treatment with riamilovir (Triazavirin®) in sick children aged 12–17 years with a diagnosis of ARVI was shown. A decrease in the duration of the disease was shown when using the drug riamilovir (Triazavirin®) compared with the control group. No serious adverse events were detected during the study.

Conclusion. As a result of the conducted clinical study, the high efficacy, safety and good tolerability of the drug riamilovir in the treatment of children aged 12–17 years with a diagnosis of ARVI was established. It is recommended to use the drug riamilovir in clinical practice as an etiotropic therapy in children aged 12–17 years with a diagnosis of ARVI due to its high efficacy and safety.

About the authors

Alebai U. Sabitov

Ural State Medical University

Author for correspondence.
Email: postdiplom@usma.ru
ORCID iD: 0000-0003-0858-9529

д-р мед. наук, проф., зав. каф. инфекционных болезней и клинической иммунологии

Russian Federation, Yekaterinburg

Olga P. Kovtun

Ural State Medical University

Email: postdiplom@usma.ru
ORCID iD: 0000-0002-5250-7351

акад. РАН, д-р мед. наук, проф., ректор

Russian Federation, Yekaterinburg

Elena V. Esaulenko

Saint Petersburg State Pediatric Medical University

Email: postdiplom@usma.ru
ORCID iD: 0000-0003-3669-1993

д-р мед. наук, проф., зав. каф. инфекционных болезней взрослых и эпидемиологии

Russian Federation, Saint Petersburg

Pavel V. Sorokin

“Pharmaviron” LLC

Email: postdiplom@usma.ru
ORCID iD: 0000-0002-1477-8521

канд. фарм. наук, ген. дир.

Russian Federation, Novouralsk

References

  1. Острая респираторная вирусная инфекция (ОРВИ). Федеральные клинические рекомендации Министерства здравоохранения России. М., 2022. Режим доступа: https://cr.minzdrav.gov.ru/recomend/25_2. Ссылка активна на 05.11.2022 [Ostraia respiratornaia virusnaia infektsiia (ORVI). Federal'nye klinicheskie rekomendatsii Ministerstva zdravookhraneniia Rossii. Moscow, 2022. Available at: https://cr.minzdrav.gov.ru/recomend/25_2. Accessed: 05.11.2022 (in Russian)].
  2. Ключников С.О. Острые респираторные заболевания у детей: учебно-методическое пособие. М., 2009 [Kliuchnikov SO. Ostrye respiratornye zabolevaniia u detei: uchebno-metodicheskoe posobie. Moscow, 2009 (in Russian)].
  3. О заболеваемости гриппом и ОРВИ. Режим доступа: http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357. Ссылка активна на 18.11.2022 [O zabolevaemosti grippom i ORVI. Available at: http://36.rospotrebnadzor.ru/key-areas/prevention-infectious-diseases/statistics/15357. Accessed: 18.11.2022 (in Russian)].
  4. WHO. Global Health estimates. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed: 18.11.2022 (in Russian)].
  5. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2(1):25-32. doi: 10.1016/S1473-3099(01)00170-0
  6. Avendaño Carvajal L, Perret Pérez C. Epidemiology of Respiratory Infections. Pediatric Respiratory Diseases. Cham: Springer International Publishing, 2020. doi: 10.1007/978-3-030-26961-6_28
  7. Ma X, Conrad T, Alchikh M, et al. Can we distinguish respiratory viral infections based on clinical features? A prospective pediatric cohort compared to systematic literature review. Rev Med Virol. 2018;28:e1997.
  8. Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ. 2013;347:f7027. doi: 10.1136/bmj.f7027
  9. Ilechukwu GC, Ilechukwu CGA, Ubesie AC, et al. Otitis media in children: review article. Open J Pediatr. 2014;04(01):47-53. doi: 10.4236/ojped.2014.41006
  10. Еженедельный бюллетень по гриппу и ОРВИ. ФГБУ «НИИ гриппа им. А.А. Смородинцева» Минздрава России. Режим доступа: https://www.influenza.spb.ru/system/epidemic_situation/laboratory_diagnostics/ Ссылка активна на 18.11.2022 [Ezhenedel'nyi biulleten' po grippu i ORVI. FGBU «NII grippa im. A.A. Smorodintseva» Minzdrava Rossii. Available at: https://www.influenza.spb.ru/system/epidemic_situation/laboratory_diagnostics/ Accessed: 18.11.2022 (in Russian)].
  11. Грипп у взрослых. Федеральные клинические рекомендации Министерства здравоохранения России. М., 2017. Режим доступа: https://cr.minzdrav.gov.ru/recomend/604_1. Ссылка активна на 18.11.2022 [Gripp u vzroslykh. Federal'nye klinicheskie rekomendatsii Ministerstva zdravookhraneniia Rossii. Moscow, 2017. Available at: https://cr.minzdrav.gov.ru/recomend/604_1. Accessed: 18.11.2022 (in Russian)].
  12. Острая респираторная вирусная инфекция у взрослых. Федеральные клинические рекомендации Министерства здравоохранения России. M., 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/724_1. Ссылка активна на 18.11.2022 [Ostraia respiratornaia virusnaia infektsii u vzroslykh. Federal'nye klinicheskie rekomendatsii Ministerstva zdravookhraneniia Rossii. Moscow, 2021. Available at: https://cr.minzdrav.gov.ru/recomend/724_1. Accessed: 18.11.2022 (in Russian)].
  13. Деева Э.Г., Киселев О.И., Мельникова Т.И., и др. Новый противовирусный препарат «Триазавирин». Результаты I фазы клинического исследования. Эпидемиология и инфекционные болезни. 2013;18(5):20-6 [Deeva EG, Kiselev OI, Melnikova TI, et al. New antiviral drug Triazavirin. Results of phase 1 clinical trial. Epidemiology and Infectious Diseases. 2013;18(5):20-6 (in Russian)]. doi: 10.17816/EID40768
  14. Киселев О.И., Деева Э.Г., Мельникова Т.И., и др. Новый противовирусный препарат Триазавирин. Результаты II фазы клинического исследования. Вопросы вирусологии. 2012;57(6):9-12 [Kiselev OI, Deyeva EG, Melnicova TI, et al. A new antiviral drug triazavirin: Results of phase II clinical trial. Vopr Virusol. 2012;57(6):9-12 (in Russian)].
  15. Сологуб Т.В., Токин И.И., Мидикари А.С., Цветков В.В. Сравнительная эффективность и безопасность применения противовирусных препаратов в терапии больных гриппом. Инфекционные болезни. 2017;15(3):25-32 [Sologub TV, Tokin II, Midikari AS, Tsvetkov VV. A comparative efficacy and safety of using antiviral drugs in therapy of patients with influenza. Infekc Bolezn. 2017;15(3):25-32 (in Russian)]. doi: 10.20953/1729-9225-2017-3-25-32
  16. Токин И.И., Зубкова Т.Г., Дроздова Ю.В., Лиознов Д.А. Опыт этиотропной терапии ОРВИ отечественным противовирусным препаратом. Инфекционные болезни. 2019;17(4):13-7 [Tokin II, Zubkova TG, Drozdova YuV, Lioznov DA. Experience of etiotropic therapy of acute respiratory viral infection with domestic antiviral drug. Infectious Diseases. 2019;17(4):13-7 (in Russian)]. doi: 10.20953/1729-9225-2019-4-13-17
  17. Лиознов Д.А., Токин И.И., Зубкова Т.Г., Сорокин П.В. Практика применения отечественного противовирусного препарата в этиотропной терапии острой респираторной вирусной инфекции. Терапевтический архив. 2020;92(12):160-4 [Lioznov DA, Tokin II, Zubkova TG, Sorokin PV. The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(12):160-4 (in Russian)]. doi: 10.26442/00403660.2020.12.200427
  18. Сабитов А.У., Ковтун О.П., Бацкалевич Н.А., и др. Метаанализ рандомизированных контролируемых клинических исследований эффективности препарата Риамиловир в этиотропной терапии острой респираторной вирусной инфекции. Антибиотики и химиотерапия. 2021;66(5-6):48-57 [Sabitov AU, Kovtun OP, Batskalevich NA, et al. Meta-analysis of randomized controlled clinical trials of Riamilovir efficacy in the etiotropic therapy of acute respiratory viral infection. Antibiotics and Chemotherapy. 2021;66(5-6):48-57 (in Russian)]. doi: 10.37489/0235-2990-2021-66-5-6-48-57
  19. Сабитов А.У., Ковтун О.П., Бацкалевич Н.А., и др. Метаанализ рандомизированных клинических исследований эффективности препарата Риамиловир в этиотропной терапии гриппа. Антибиотики и химиотерапия. 2021;66(5-6):58-71 [Sabitov AU, Kovtun OP, Batskalevich NA, et al. Meta-analysis of randomized clinical trials of Riamilovir efficacy in etiotropic therapy of influenza. Antibiotics and Chemotherapy. 2021;66(5-6):58-71 (in Russian)]. doi: 10.24411/0235-2990-2021-66-5-6-58-71
  20. Деева Э.Г., Киселев О.И., Мельникова Т.И., и др. Новый противовирусный препарат «Триазавирин». Результаты I фазы клинического исследования. Эпидемиология и инфекционные болезни. 2013;18(5):20-6 [Deeva EG, Kiselev LI, Melnikova TI, et al. New antiviral drug Triazavirin. Results of phase 1 clinical trial. Epidemiol Infect Dis. 2013;18(5):20-6 (in Russian)]. doi: 10.17816/EID40768

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Total etiological structure of respiratory viruses in patients with ARVI (n=232) at the screening stage, %.

Download (137KB)
Indexing metadata
3. Fig. 2. Kaplan–Meyer survival analysis curve of the time of onset of persistent improvement of clinical symptoms on the scale of severity of the ARVI condition by groups.

Download (89KB)
Indexing metadata
4. Fig. 3. Analysis curve of time from the moment of beginning of treatment to normalization of temperature by groups.

Download (82KB)
Indexing metadata
5. Fig. 4. The analysis curve of the time of onset of complete disappearance of clinical symptoms on the scale of severity of the ARVI condition by groups.

Download (80KB)
Indexing metadata
6. Fig. 5. The time curve from the onset to the end of qatar syndrome.

Download (79KB)
Indexing metadata

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies